Other potential targetable genetic alterations were found in less than 10% cases: the RET gene fusion was found in 8%, NTRK1 and 3 gene fusion in 3%, and other mutations in less than 2% of classic papillary thyroid cancers. The gene discussed is NTRK1; the disease is thyroid gland papillary carcinoma.